Cullinan Therapeutics Inc (CGEM) Stock Price, Quote & News

Company Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its deve...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 410 4650

Website: cullinantherapeutics.com

Address:

One Main Street, Suite 1350, Cambridge, United States

MoneyGroupLLC Dec. 24 at 5:25 AM

Enter: $CGEM Calls Strike Price: $11 Expiry Date: JAN 16 2026 Buy in Price: $0.55 - $0.58 Sell Price: $1.08 Profit : +97% (Turn every $1 into $1.97) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 22 at 11:25 AM

Enter: $CGEM Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.90 - $1.20 Sell Price: $1.50 Profit : +67% (Turn every $1 into $1.67) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 20 at 10:22 AM

Enter: $CGEM Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.94 - $1.10 Sell Price: $2.04 Profit : +117% (Turn every $1 into $2.17) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 19 at 10:10 AM

Enter: $CGEM Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.92 - $1.35 Sell Price: $1.86 Profit : +102% (Turn every $1 into $2.02) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

starbucks_cups_with_rum Dec. 18 at 9:02 PM

$CGEM regret

0 · Reply

MoneyGroupLLC Dec. 18 at 9:29 AM

Enter: $CGEM Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.92 - $1.35 Sell Price: $1.47 Profit : +60% (Turn every $1 into $1.60) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 17 at 12:42 PM

Enter: $CGEM Calls Strike Price: $11 Expiry Date: JAN 16 2026 Buy in Price: $1.55 - $1.90 Sell Price: $2.22 Profit : +43% (Turn every $1 into $1.43) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 16 at 8:25 AM

Enter: $CGEM Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $0.92 - $1.05 Sell Price: $1.63 Profit : +77% (Turn every $1 into $1.77) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 15 at 3:16 PM

Enter: $CGEM Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.58 - $2.60 Sell Price: $2.72 Profit : +72% (Turn every $1 into $1.72) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 14 at 11:09 AM

0 · Reply

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Dec 8, 2025, 10:31 AM EST - 16 days ago

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

$Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia$

Dec 1, 2025, 7:00 AM EST - 23 days ago

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Nov 20, 2025, 7:00 AM EST - 4 weeks ago

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Nov 10, 2025, 7:00 AM EST - 6 weeks ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Nov 6, 2025, 7:00 AM EST - 6 weeks ago

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:11 AM EST - 7 weeks ago

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Oct 25, 2025, 11:01 AM EDT - 2 months ago

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Oct 17, 2025, 7:01 AM EDT - 2 months ago

Cullinan Therapeutics: Worthy Of A Small Position

Oct 13, 2025, 12:46 PM EDT - 2 months ago

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Oct 12, 2025, 6:27 PM EDT - 2 months ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Sep 12, 2025, 7:00 AM EDT - 3 months ago

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 10, 2025, 10:50 AM EDT - 3 months ago

Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 5:30 AM EDT - 3 months ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Aug 21, 2025, 4:05 PM EDT - 4 months ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Aug 7, 2025, 7:00 AM EDT - 4 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 15, 2025, 10:24 PM EDT - 5 months ago

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst

Jun 4, 2025, 4:02 PM EDT - 7 months ago

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Jun 1, 2025, 8:21 AM EDT - 7 months ago

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

May 29, 2025, 7:00 AM EDT - 7 months ago

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

May 22, 2025, 5:15 PM EDT - 7 months ago

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

May 8, 2025, 7:00 AM EDT - 8 months ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 8 months ago

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

Apr 23, 2025, 10:14 AM EDT - 8 months ago

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Apr 16, 2025, 7:00 AM EDT - 9 months ago

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Feb 27, 2025, 7:00 AM EST - 10 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 7:00 PM EST - 11 months ago

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Jan 9, 2025, 11:11 PM EST - 1 year ago

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

Jan 8, 2025, 5:26 PM EST - 1 year ago

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Nov 14, 2024, 10:01 AM EST - 1 year ago

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Sep 14, 2024, 4:15 AM EDT - 1 year ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Jun 1, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

May 24, 2024, 8:00 AM EDT - 1 year ago

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024, 5:04 PM EDT - 1 year ago

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 15, 2024, 4:05 PM EDT - 1 year ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Apr 24, 2024, 10:09 AM EDT - 1 year ago

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Apr 16, 2024, 6:59 AM EDT - 1 year ago

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

$Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma$

Mar 1, 2024, 7:00 AM EST - 1 year ago

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cullinan Oncology to Participate in Upcoming Investor Conferences

Dec 18, 2023, 4:53 PM EST - 2 years ago

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 4:30 PM EST - 2 years ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Nov 8, 2023, 7:00 AM EST - 2 years ago

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 3, 2023, 12:01 PM EDT - 2 years ago

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

MoneyGroupLLC Dec. 24 at 5:25 AM

0 · Reply

MoneyGroupLLC Dec. 22 at 11:25 AM

0 · Reply

MoneyGroupLLC Dec. 20 at 10:22 AM

0 · Reply

MoneyGroupLLC Dec. 19 at 10:10 AM

0 · Reply

starbucks_cups_with_rum Dec. 18 at 9:02 PM

$CGEM regret

0 · Reply

MoneyGroupLLC Dec. 18 at 9:29 AM

0 · Reply

MoneyGroupLLC Dec. 17 at 12:42 PM

0 · Reply

MoneyGroupLLC Dec. 16 at 8:25 AM

0 · Reply

MoneyGroupLLC Dec. 15 at 3:16 PM

0 · Reply

MoneyGroupLLC Dec. 14 at 11:09 AM

0 · Reply

MoneyGroupLLC Dec. 12 at 9:08 AM

Enter: $CGEM Calls Strike Price: $14 Expiry Date: JAN 16 2026 Buy in Price: $1.00 - $5.00 Sell Price: $1.73 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 11 at 2:32 PM

Enter: $CGEM Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.30 - $2.55 Sell Price: $2.56 Profit : +97% (Turn every $1 into $1.97) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

RunnerSignals Dec. 10 at 8:32 PM

2/4 Stock Upgrades Today $CGEM $OCUL $BWMN $SRAD $SW Pipeline catalysts firing on all cylinders this could be your breakout week with these stocks https://stocksrunner.com/news/2025-12-10-stock-upgrades-today-show-top-picks

0 · Reply

ClinicalTrialsDaily Dec. 10 at 3:26 PM

$CGEM Clinical data is solid. 31% CR/CRh in R/R AML is competitive, but the 50% hit rate in TP53 mutants is the real differentiator for hematologists. FDA Fast Track well deserved. #ASH25 #Biotech Analysis at ClinicalTrialsDaily (.com)

0 · Reply

MoneyGroupLLC Dec. 10 at 6:19 AM

Enter: $CGEM Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.30 - $2.20 Sell Price: $2.65 Profit : +104% (Turn every $1 into $2.04) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

bpeeters Dec. 9 at 6:28 PM

$CGEM hoping we bounce soon and push higher. Last time we faded up here

0 · Reply

anachartanalyst Dec. 9 at 4:03 PM

$CGEM https://anachart.com/wp-content/uploads/ana_temp/1765296181_soc-img.jpg

0 · Reply

JarvisFlow Dec. 9 at 1:18 PM

Wedbush has updated their rating for Cullinan Therapeutics ( $CGEM ) to Outperform with a price target of 34.

0 · Reply

jlcasante Dec. 9 at 9:35 AM

$CGEM 25

1 · Reply

MoneyGroupLLC Dec. 9 at 5:10 AM

Enter: $CGEM Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.00 - $1.50 Sell Price: $2.01 Profit : +101% (Turn every $1 into $2.01) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

traderk1836 Dec. 8 at 11:42 PM

$CGEM CGEM Approaches Key Breakout Level After Heavy Volume Surge https://www.therelativestrengthtrader.com/2025/12/cgem-approaches-key-breakout-level.html

0 · Reply

lenten Dec. 8 at 10:38 PM

$BACQ $AEVA $TORO $CGEM $QCLS

0 · Reply

Market Cap	590.76M
Revenue (ttm)	0.00
Net Income (ttm)	-167.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	302,400
Avg Vol	1,196,544
Day's Range	N/A - N/A
Shares Out	59.08M
Stochastic %K	23%
Beta	-0.10
Analysts	Strong Sell
Price Target	$29.50